Sinopharm (1099 HK): Top Distributor of Pharma Products in China

China Medical Devices: "Two-Invoice" Is Coming

Initiating Coverage of Sinopharm with Narrow Moat Rating, FVE of HKD 36 Per Share

APAC IPOs & Placements

Zhen Zhou, Toh

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Sinopharm Group Co Ltd H / Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/sinopharm-group-co-h" target="_blank" data-smartkarma-citation="entities:32:1" rel="noopener">Sinopharm Group Co H (1099 HK)</a> is looking to raise about US$539m in its placement. </p><p>Overall, the deal scores negatively on our framework owing to the poor track record and large deal size. Recent results haven't exactly been stellar either as margins pressure seem to be persisting. However, to be fair, the company is trading at inexpensive valuations.</p>

Sinopharm Group Co H (1099 HK) is looking to raise about US$539m in its placement. Overall, the deal scores negatively on our framework owing to the poor track record and large deal size. Recent results haven't exactly been stellar either as margins pressure seem to be persisting. However, to be fair, the company is trading at inexpensive valuations.

Sinopharm (国医控股) Placement - Unattractive but Inexpensive